GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2009

Ablynx and Novartis Ink One-Year Extension

  • Ablynx’ drug discovery and development alliance with Novartis has been extended for another year. The original deal was signed in December 2005, and an extension was made in December 2007.

    The agreement covers Nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive rights to develop and commercialize any resulting products.

    Ablynx receives license fees and funding for research and development. The company is also eligible for milestone payments and royalties.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »